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A B S T R A C T
Background
A macular hole is an anatomic opening in the retina that develops at the fovea. Macular holes can be seen in highly myopic eyes or
following ocular trauma, but the great majority are idiopathic. Pars plana vitrectomy was introduced to treat full-thickness macular
holes, which if left untreated have a poor prognosis since spontaneous closure and visual recovery are rare.
Vitrectomy is a surgical technique involving the removal of the vitreous body that fills the eye. The surgeon inserts thin cannulas into
the eyes through scleral incisions to relieve traction exerted by the vitreous or epiretinal membranes to the central retina and to induce
glial tissue to bridge and close the hole.
Objectives
The primary objective of this review was to examine the effects of vitrectomy for idiopathic macular hole on visual acuity. A secondary
objective was to investigate anatomic effects on hole closure and other dimensions of visual function, as well as to report on adverse
effects recorded in included studies.
Search methods
We searched the Cochrane Eyes and Vision Group Trials Register (4 March 2015), the Cochrane Central Register of Controlled Trials
(CENTRAL; 2015, Issue 2), Ovid MEDLINE, Ovid MEDLINE In-Process and Other Non-Indexed Citations, Ovid MEDLINE
Daily,OvidOLDMEDLINE (January 1946 toMarch 2015), EMBASE (January 1980 toMarch 2015), Latin American and Caribbean
Health Sciences Literature Database (LILACS) (January 1982 to March 2015), the Web of Science Conference Proceedings Citation
Index-Science (CPCI-S) (January 1980 to March 2015), the ISRCTN registry (www.isrctn.com/editAdvancedSearch), ClinicalTri-
als.gov (www.clinicaltrials.gov) and the World Health Organization (WHO) International Clinical Trials Registry Platform (ICTRP)
(www.who.int/ictrp/search/en). We did not use any date or language restrictions in the electronic searches for trials. We last searched
the electronic databases on 4 March 2015.
Selection criteria
We included randomised controlled trials comparing vitrectomy (with or without internal limiting membrane peeling) to no treatment
(that is observation) for macular holes.
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Data collection and analysis
Weused standardmethodological procedures expected byCochrane. Two review authors independently extracted the data.We estimated
best corrected visual acuity and macular hole closure at 6 to 12 months of follow-up.
Main results
Three studies provided data on the comparison between vitrectomy and observation in eyes with macular hole and visual acuity less
than 20/50. Two studies, conducted in the USA and published in 1996 and 1997, used a similar protocol and included participants
with stage II macular hole (42 eyes randomised, 36 analysed, number of participants not reported) or participants with stage III/IV
hole (129 eyes of 120 participants, 115 eyes in analyses). The third study, conducted in the UK and published in 2004, included 185
eyes of 174 participants with full-thickness macular hole (41 eyes with stage II holes and 74 eyes with stage III/IV holes in analyses).
Studies were of good quality for randomisation and allocation concealment, whereas visual acuity measurement was unmasked.
At 6 to 12 months, visual acuity was improved by about 1.5 Snellen lines (-0.16 logMAR, 95% confidence intervals -0.23 to -0.09
logMAR, 270 eyes, moderate-quality evidence). The chances of macular hole closure at 6 to 12 months were greatly increased using
vitrectomy, yielding an odds ratio of 31.4 (95% confidence intervals 14.9 to 66.3, 265 eyes, high-quality evidence; raw sum data: 76%
vitrectomy, 11% observation). Vitrectomy was beneficial both in smaller (stage II) and in larger (stage III/IV) macular holes.
The largest study reported that cataract surgery was needed in about half of cases at two years after operation and that retinal detachment
occurred in about 5% of operated eyes.
Authors’ conclusions
Vitrectomy is effective in improving visual acuity, resulting in a moderate visual gain, and in achieving hole closure in people with
macular hole. However, these results may not apply to modern surgery due to technological improvements in vitrectomy techniques.
P L A I N L A N G U A G E S U M M A R Y
Vitrectomy for idiopathic macular hole
Background
A macular hole is an opening in the retina (the layer at the back of the eye that is sensitive to light) that develops at the fovea (the
part of the eye that is responsible for sharp vision) and causes a small dark spot in the central vision, often preventing those with the
condition from recognising very small objects, and particularly from reading ordinary print. Macular holes can be seen in people with
highly myopic eyes (who cannot see clearly in the distance) or following ocular trauma, but in the great majority of cases the cause is
unknown (idiopathic).
Pars plana vitrectomy has been used for more than a decade to treat full-thickness macular holes, which if left untreated cause a blind
spot in central vision that only rarely improve naturally. Vitrectomy is a surgical technique involving the removal of the vitreous body
(the clear gel that fills the eye). The surgeon inserts thin tubes called cannulas into the eyes through scleral (white part of the eye)
incisions or incision of the eye wall to relieve traction exerted by the vitreous to the central retina and close the hole. The objective of
this review was to examine the effects on visual acuity of vitrectomy for idiopathic macular hole.
Study characteristics
We included three studies, published between 1996 and 2004 and conducted in the USA and the UK, including 270 eyes in analyses,
comparing vitrectomy and observation after 6 or 12 months. The evidence is current as of March 2015.
Key results
Vitrectomy improved visual acuity in participants with macular hole by about 1.5 lines of a standard distance acuity chart. Macular
hole closure was much more likely with vitrectomy compared to observation, with mean closure rates of 76% versus 11%, respectively.
Cataract surgery was common in operated eyes. In the largest study, retinal detachment occurred in the months following vitrectomy
in about 5% of cases.
Quality of the evidence
The evidence was of moderate quality, as the visual acuity measurement was unmasked.
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Conclusion
Vitrectomy is effective in improving visual acuity, resulting in a moderate visual gain, and in achieving hole closure in people with
macular hole. However, as vitrectomy technology has improved since the included trials were conducted, with use of a smaller incision
and outpatient care, the results of this review may not apply to modern surgery.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Vitrectomy compared to observation for idiopathic macular hole
Patient or population: participants with idiopathic macular hole
Settings:
Intervention: vitrectomy
Comparison: observation
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of Participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
Observation Vitrectomy
Mean visual acuity (log-
MAR) at 6-12 months
Follow-up: 6-12 months
The mean visual acuity
(logMAR) at 6-12 months
in the control groups was
0.6 to 0.9 logMAR
The mean visual acuity
(logMAR) at 6-12 months
in the intervention groups
was
-0.16 logMAR better
(-0.23 to -0.09)
- 270 eyes
(3 studies)
⊕⊕⊕©
moderate1
-
Hole closure at 6-12
months
Follow-up: 6-12 months
110 per 1000 796 per 1000
(649 to 891)
OR 31.4
(14.9 to 66.3)
265
(3 studies)
⊕⊕⊕⊕
high2
-
Reading acuity at 6
months
The mean reading acuity
at 6 months in the control
groups was
0.8 to 1.0 logMAR
The mean reading acuity
at 6 months in the inter-
vention groups was
-0.17 better
(-0.26 to -0.07 better)
- 154
(2 studies)
⊕⊕©©
low1,3
-
Reading speed (word/
minute) at 6 months
The mean reading speed
(word/minute) at 6
months in the control
groups was
36 words/minute
The mean reading speed
(word/minute) at 6
months in the intervention
groups was
5.6 lower
- 118
(1 study)
⊕⊕©©
low1,3
-
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(14.42 lower to 3.22
higher)
Hole recurrence Data on macular hole recurrence after initially successful surgery could not be extracted from the studies
Adverse outcomes Retinal detachment: Freeman 1997 reported no cases; Ezra 2004 described the retinal detachment rate for the vitrectomy groups only (vitrectomy alone or with
serum), with values of 7/124 (5.6%), most detachments occurring in the first 6 weeks
Symptomatic visual field defects (Ezra 2004) in the inferotemporal sector were found in 4/124 eyes (3.2%), with 15 eyes (12.1%) having asymptomatic defects
Re-operation (Ezra 2004): 18 (14.5%) of the surgical eyes, with subsequent hole closure in 78% of cases
Costs Cost data were not available in the included studies.
*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is based on the
assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
CI: confidence interval; OR: odds ratio
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality: We are very uncertain about the estimate.
1 No or unclear masking of participant, physician, or outcome assessor (-1)
2 No downgrade, as a result of no or unclear masking of outcome assessor in one study (-1), but upgraded because of strong effect
(+1)
3 Wide confidence interval (-1)
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B A C K G R O U N D
Description of the condition
A macular hole is an anatomic opening in the retina that develops
at the fovea. Macular holes can be seen in highly myopic eyes or
following ocular trauma, but the great majority are idiopathic (Ho
1998).
Idiopathic macular hole is a rather common retinal disease affect-
ing elderly people. The Beaver Dam Study found full-thickness
macular holes to be prevalent in 0.3% of the population, with
prevalence rates increasing from 0% in those between 43 and 54
years of age to 0.8% in people aged 75 years or more (Klein 1994).
In a case-control study, 72% of idiopathic macular holes occurred
in women and more than 50% occurred in people 65 to 74 years
old. The study found that only 3% were occurred in people under
the age of 55 years (de Bustros 1994).
The five-year risk for developing a full-thickness macular hole in
the fellow eye of a person with a full-thickness macular hole in one
eye is about 10% to 15% (Ezra 1998; Freeman 1997; Kim 1996).
The pathogenesis of idiopathic full-thickness macular holes is be-
lieved to involve anteroposterior traction, tangential traction, or
both, exerted by the posterior vitreous cortex at the fovea (Azzolini
2001; Gass 1988; Gaudric 1999; Tanner 2001).
Macular hole formation typically evolves over a period of weeks or
months through a series of stages first described biomicroscopically
by Gass (Gass 1988; Gass 1995).
• Stage IA: central yellow spot, loss of foveolar depression, no
vitreofoveolar separation.
• Stage IB: yellow ring with bridging interface, loss of
foveolar depression, no vitreofoveolar separation.
• Stage II: eccentric oval, crescent or horseshoe retinal defect
inside edge of yellow ring, central round retinal defect with rim
of elevated retina, with or without prefoveolar opacity.
• Stage III: central round retinal defect ≥ 400 microns
diameter, no Weiss’s ring, rim of elevated retina, with or without
prefoveolar opacity.
• Stage IV: central round retinal defect, rim of elevated
retina, Weiss’s ring, with or without prefoveolar opacity.
Since its introduction, optical coherence tomography (OCT) has
been recognised as an extremely useful tool for making or con-
firming diagnoses of macular hole, as well as for defining the stage
of the lesion (Hee 1995).
A detailed staging based on OCT observations was recently pro-
posed (Altaweel 2003).
• Stage IA: foveal splitting, a pseudocyst visible on OCT
prior to the clinically recognised yellow spot.
• Stage IB: pseudocyst enlargement and extension to the
outer retina with roof intact.
• Stage IIA: full-thickness macular hole (diameter < 400
microns) with posterior hyaloid face remaining attached to roof
of pseudocyst.
• Stage IIB: full-thickness macular hole (diameter < 400
microns) with operculum.
• Stage III: full-thickness macular hole (diameter > 400
microns) with surrounding thickened retina including
intraretinal cystoid spaces. The perifoveal and prefoveal hyaloid
is separated from the macular retina.
• Stage IV: a stage III hole with a complete posterior vitreous
detachment. OCT often cannot visualise the posterior hyaloid
because it is too anterior.
The prognosis of untreated full-thickness macular holes is poor.
Approximately 5% will have 20/50 visual acuity or better; 55% to
58%will have visual acuity of 20/100 or better; and approximately
40% will have visual acuity of 20/200 or worse (Casuso 2001;
Chew 1999; Hikichi 1993; Lewis 1996; Morgan 1985). About
75% of stage II macular holes progress to a full-thickness stage III
or stage IV macular hole (Guyer 1992; Hikichi 1995a; Hikichi
1995b; Kim 1995; Kim 1996).
The fellow eyes of people with macular holes have an approxi-
mately 10% to 20% risk of developing a macular hole, especially
if the hyaloid remains attached (Lewis 1996).
Description of the intervention
In 1991, Kelly et al introduced the use of pars plana vitrectomy
to treat macular holes (Kelly 1991). Vitrectomy is a surgical tech-
nique involving the removal of the vitreous body that fills the eye
using thin cannulas that are inserted into the eyes through scle-
ral incisions. Pars plana vitrectomy is a vitrectomy with separa-
tion of the vitreous from the retinal surface, and may include re-
moval (peeling) of any fibrous membranes adherent to the retina
(epiretinal membranes), filling the eye with long-acting gas (tam-
ponade), and positioning of the patient strictly face-down for the
first days after the operation. The surgical objective is to relieve
traction exerted by the vitreous or by epiretinal membranes to the
central retina and to induce glial tissue to bridge and close the
hole. The effectiveness of face-down positioning is the subject of
another Cochrane review (Solebo 2011), while that of internal
limiting membrane (ILM) peeling has been demonstrated by yet
another review (Spiteri Cornish 2013). To achieve reproducible,
complete, and atraumatic ILM peeling, the use of a vital dye (in-
docyanine green or trypan blue) or triamcinolone has been advo-
cated to facilitate its clear identification (Da Mata 2001; Li 2003;
Lochhead 2004; Perrier 2003; Spiteri Cornish 2013; Teba 2003;
Wolf 2003). Intraoperative adjuvants such as transforming growth
factor-2 (Glaser 1992; Smiddy 1993; Thompson 1998), serum
(Banker 1999; Kusaka 1997, Ligget 1995), an absorbable partially
cross-linked gelatin (collagen) plug (Peyman 1997), thrombin-ac-
tivated fibrinogen (Olsen 1998), plasmin (Margherio 1998; Trese
2000), thrombin (Olsen 1998; Vine 1996), and a plasma-throm-
bin mixture (Blumenkranz 2001) have been studied. Other vari-
ations in surgical technique include retinal tamponade by differ-
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ent methods at the end of macular hole surgery to help flatten
the macular hole and achieve closure, such as using octafluoro-
propane, sulfur hexafluoride (Mulhern 2000; Thompson 1996;
Thompson 1998), or air tamponade (Brooks 2000; Park 1999).
Silicone oil has been recommended for people who cannot be po-
sitioned postoperatively or who need to travel in aeroplanes soon
after surgery (Goldbaum 1998; Pertile 1999).
Surgical techniques and outcomes have improved over the last two
decades, with many case series now reporting primary anatomical
closure following conventional surgery in more than 90% of eyes
with full-thickness macular holes (Margherio 2000; Polk 1996;
Smiddy 1997).
Why it is important to do this review
Although vitrectomy for macular hole is now well established, a
systematic review of these treatment modalities is useful to pa-
tients, ophthalmologists, and other professionals involved in pro-
viding eye health care in order to assess the role of vitrectomy in
the treatment of macular holes and to outline the differences be-
tween the different techniques, should there be any.
O B J E C T I V E S
The primary objective of this review was to examine the effects
of vitrectomy for idiopathic macular hole on visual acuity. A sec-
ondary objective was to investigate anatomic effects on hole clo-
sure and other dimensions of visual function, as well as to report
on adverse effects recorded in included studies.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We planned to include randomised controlled trials (RCTs) and
quasi-RCTs. Quasi-RCTs are trials in which the methods of allo-
cating people to interventions are not truly random, such as date
of birth, day of the week, etc.
Types of participants
Participants were people affected by any stage of idiopathic mac-
ular hole.
Types of interventions
We included studies in which vitrectomy (with or without ILM
peeling) was compared to no treatment (that is observation). We
considered that a sham procedure was not feasible or ethical when
compared with vitreous surgery.
Types of outcome measures
Primary outcomes
1. Best corrected visual acuity on a continuous scale after at
least one year of follow-up (plus or minus six months).
Secondary outcomes
1. Best corrected visual acuity recorded yearly after 12 months.
2. Anatomic closure of macular hole at the first intervention.
3. Rate of macular hole recurrences.
4. Contrast sensitivity, reading acuity and speed, or any other
validated measures of visual function as available in the studies;
these were expressed on a continuous scale.
5. Quality of life measures: any validated measurement scale
that aims to measure the impact of visual function loss on quality
of life of participants.
6. Economic data: we had planned to perform comparative
cost analysis if data were available.
Adverse effects
Any reported adverse outcomes, particularly retinal detachment.
We based the conclusions of this review on the primary outcome
’best corrected visual acuity’ in order to minimise the impact of
reporting biases and multiplicity of outcome measures.
Search methods for identification of studies
Electronic searches
We searched the Cochrane Eyes and Vision Group Trials Register
(4March 2015), the Cochrane Central Register of Controlled Tri-
als (CENTRAL; 2015, Issue 2), Ovid MEDLINE, Ovid MED-
LINE In-Process and Other Non-Indexed Citations, Ovid MED-
LINE Daily, Ovid OLDMEDLINE (January 1946 to March
2015), EMBASE (January 1980 to March 2015), Latin Ameri-
can and Caribbean Health Sciences Literature Database (LILACS)
(January 1982 to March 2015), the Web of Science Con-
ference Proceedings Citation Index-Science (CPCI-S) (January
1980 to March 2015), the ISRCTN registry (www.isrctn.com/
editAdvancedSearch), ClinicalTrials.gov (www.clinicaltrials.gov)
and the World Health Organization (WHO) International Clini-
cal Trials Registry Platform (ICTRP) (www.who.int/ictrp/search/
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en). We did not use any date or language restrictions in the elec-
tronic searches for trials. We last searched the electronic databases
on 4 March 2015.
See: Appendices for details of search strategies for CENTRAL
(Appendix 1),MEDLINE (Appendix 2), EMBASE (Appendix 3),
LILACS (Appendix 4), CPCI-S (Appendix 5), mRCT (Appendix
6), ClinicalTrials.gov (Appendix 7) and the ICTRP (Appendix 8).
Searching other resources
We handsearched the reference lists of the included trials for other
possible trials but found no additional studies.
Data collection and analysis
We used standard methodological procedures expected by
Cochrane.
Selection of studies
Two review authors independently selected the studies for inclu-
sion. The review authors examined the titles and abstracts of all re-
ports identified by the electronic searches and handsearching and
classified them as (a) definitely include, (b) unsure, or (c) definitely
exclude. The review authors obtained full-text copies of the ti-
tles and abstracts classified as (a) definitely include and (b) unsure
and reclassified them as (1) included, (2) awaiting assessment, or
(3) excluded. We contacted the authors of studies classified as (2)
awaiting assessment for further clarification and re-assessed them
as more information became available. In particular, we contacted
the leading author of Freeman 1997 for additional data on ran-
domisation and masking procedures. We excluded studies identi-
fied by both review authors as (3) excluded, and we documented
these in the review. We included studies identified as (1) included
and assessed these for risk of bias. The review authors were un-
masked to the report authors, institutions, and trial results during
this assessment. Disagreements between the two review authors
were resolved by referral to a third review author.
Data extraction and management
Two review authors independently extracted the data for the pri-
mary and secondary outcomes onto paper data extraction forms
developed by the Cochrane Eyes and Vision Group. We resolved
discrepancies by discussion.
One review author entered the data into Review Manager
(RevMan 2014), and another review author checked the data.
Assessment of risk of bias in included studies
Two review authors independently assessed the included trials
for bias according to the methods described in Chapter 8 of the
Cochrane Handbook for Systematic Reviews of Interventions (Higgins
2011a). We assessed the following parameters: sequence genera-
tion; allocation concealment; masking (blinding) of outcome as-
sessors (masking of participants and study personnel was not pos-
sible for a surgical procedure); incomplete outcome data; and se-
lective outcome reporting. We evaluated these items for each out-
come measure or class of outcome measure as specified in the
latest version of the Cochrane Handbook for Systematic Reviews of
Interventions. As reported in the Handbook, other sources of bias
were: risk of bias related to the specific study design used; trial
stopped early due to some data-dependent process (including a
formal stopping rule); an extreme baseline imbalance; or the study
was claimed to have been fraudulent.
We used guidance contained in Chapter 11 of the Cochrane
Handbook for Systematic Reviews of Interventions (Schünemann
2011) and also guidance available on publications listed in the
GRADE website to prepare the Summary of findings for the main
comparison.
If the information available in the published trial reports was in-
adequate to assess methodological quality, we contacted the trial
authors for clarification. Specifically, we obtained unpublished in-
formation from Freeman 1997 on randomisation generation and
allocation concealment.
Measures of treatment effect
In our data analysis we followed the guidelines set out in Chapter
9 of the Cochrane Handbook for Systematic Reviews of Interventions
(Deeks 2011). We calculated a mean difference for continuous
outcomes. We planned to calculate a summary risk ratio (RR)
if dichotomous outcomes were summarised, but we discovered
difficulties in the interpretationofRRwhen the control risk varied.
We therefore chose to use the odds ratio (OR) as the measure of
association. We also derived the risk difference in the Summary of
findings for the main comparison.
We expressed the primary outcome ’best corrected visual acuity’
on a continuous scale, as functional secondary outcomes (near
acuity and reading speed). We recorded macular hole closure and
as a dichotomous variable.
Unit of analysis issues
We had considered that the unit of analysis needed to be the
individual participant. We originally planned to present studies
withmore than10%of participants providingboth eyes to analyses
as a subgroup versus other studies. However, since we included
only three studies in this review, and bearing in mind that macular
hole is mostly a unilateral disease, we decided to present data with
eyes as the unit of analysis.We acknowledged that studies included
participants with bilateral macular hole, but considered that this is
a rare condition and bias is negligible (20 of 294, 6.8%participants
with macular hole in both eyes in Freeman 1997 and Ezra 2004,
overall).
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Dealing with missing data
Where data were missing due to participant dropout, we con-
ducted a primary analysis based on participants with complete
data (available case analysis). We considered that missing outcome
data was not a problem if loss to follow-up was balanced in the
study arms and causes of loss to follow-up were documented and
judged to be unrelated to outcome in both study arms (Higgins
2011b). When causes of missing data were not available and suf-
ficient studies were found, we had originally planned to use Stata
2011 user-written function ’metamiss’ to take into account miss-
ing data and conduct sensitivity meta-analyses, as perWhite 2008.
However, metamiss can only be used for dichotomous data, such
as hole closure. As we explain later, we found a limited amount of
missing data: 9 of 174 participants (5%) were lost in Ezra 2004 at
24 months; 11 of 129 participants (8.5%) were lost in Freeman
1997 at 6 months; and 6 of 36 eyes (16.7%) were lost in Kim
1996 at 12 months.We assumed that this rather low overall rate of
missing data would not cause bias given the large effect observed
with vitrectomy.
Assessment of heterogeneity
We looked for clinical heterogeneity by examination of the study
details, then tested for statistical heterogeneity between trial results
using the Chi2 test and the I2 value (Deeks 2011). We classified
heterogeneity using the following I2 values.
• 0% to 40%: might not be important
• 30% to 60%: may represent moderate heterogeneity
• 50% to 90%: may represent substantial heterogeneity
• 75% to 100%: considerable heterogeneity
We also reported I2 values with 95% confidence intervals (CI) as
computed using Stata 12 ’heterogi’ command.
We had originally planned that if we found only one trial providing
data for one comparison, we would conduct a sensitivity analysis
on the robustness of trial results based on a recent publication
by Borm 2009. These authors presented the epidemiological and
statistical framework of the estimate of effect by a single trial. They
suggested that, assuming a heterogeneity I2 value of 0.25, 0.50,
or 0.75 in a hypothetical meta-analysis including the trial, the
robustness of the results of a single trial can be assessed by applying
an inflation factor of 1.15, 1.41, or 2.00, respectively, to the 95%
CI (on a log scale if the measure of effect is RR or OR). However,
in the review phase we decided to comment on the results with
no formal statistical simulation since three studies informed the
analyses on the most important outcomes (mean visual acuity and
hole closure), which informed our conclusions.
Assessment of reporting biases
Weplanned to assess asymmetry of the funnel plot to identify pub-
lication bias if we found at least 10 studies, but we only included
three studies in this review.
We also investigated selective outcome reporting by undertaking
an ’outcomematrix’ and classifyingmissing outcomes according to
the classification presented in Table 1 (adapted from a list provided
by PaulaWilliamson at a Cochrane training workshop on selective
outcome reporting bias; Edinburgh,March 2009).We limited this
presentation to the primary outcome.
Data synthesis
In the protocol phase, we had planned to use the following cri-
teria to synthesise the data. If there was no substantial statistical
heterogeneity and no clinical heterogeneity between the trials, we
would combine the results in a meta-analysis using a random-
effects model. We would use a fixed-effect model if the number
of trials was three or less. In case of substantial statistical (that
is I2 greater than 50%) or clinical heterogeneity, we planned not
to combine study results but to present a narrative or tabulated
summary, provided that the estimate of heterogeneity (that is I2
CI) was measured with acceptable precision, owing to a sufficient
amount of studies being found. In case substantial statistical het-
erogeneity were detected (that is a high I2 value), we would pool
the results of the studies only if examination of the forest plot
indicated that the individual trial results were all consistent in the
direction of the effect (that is the RR and CI largely fell on one
side of the null line). However, we found only three studies and
considered that we could not estimate heterogeneity precisely in
this case, so we based our assessment on the graphical exploration
of the forest plot.
Studies reported visual acuities in logMAR. We had planned to
convert Early Treatment Diabetic Retinopathy Study (ETDRS)
letter scores to logMAR for calculationswhere these were reported.
In any studies in which Snellen (decimal) visual acuity was mea-
sured by non-ETDRS or non-logarithmic charts, we had planned
to extract data only if calculations were based on logMAR trans-
formed data and the back-transformed to decimal for reporting.
We did not intend to use studies in which means and standard
deviations were computed using decimal visual acuity in meta-
analyses, but to summarise their results in the discussion.
As discussed above, we originally planned to use RRs in meta-
analyses of dichotomous outcomes such as hole closure, but then
found RRs were not suitable. They are in fact difficult to interpret
when the control risk is rather variable and the effect is very large,
such as in this case (for example a RR greater than 5 has very
differentmeaning if the control risk ranges from4% to 12% across
studies, such as in this review). To further support our choice,
we found the use of OR substantially reduced heterogeneity from
77% using RR (P equals 0.01) to 27% using OR (P equals 0.25)
regarding the outcome hole closure, and we preferred this measure
of effect.
Subgroup analysis and investigation of heterogeneity
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If we found enough studies comparing vitrectomy to observation,
we planned to conduct subgroup analyses using the following sub-
groups:
1. Macular hole stage
2. Use of adjuvants during surgery, such as vital dyes or
triamcinolone
3. Type of vitreous tamponade, i.e. air versus gas or silicone oil
4. ILM peeling or no peeling
5. Small gauge (23 or 25 gauge) surgery or conventional 20
gauge surgery
We had planned to conduct subgroup analyses only if there were
two or more studies in each subgroup. We were able to perform
subgroup analyses by hole stage (II versus III/IV), due to the fact
that Ezra 2004 provided within-study subgroup data by macular
hole stage.
Sensitivity analysis
We wanted to conduct sensitivity analyses to determine the im-
pact of exclusion of studies with lowermethodological quality, un-
published studies, quasi-randomised trials, and industry-funded
studies, but this was not possible due to sparse data.
R E S U L T S
Description of studies
Results of the search
The electronic database search yielded a total of 1504 references
(Figure 1). The Trials Search Co-ordinator removed 371 dupli-
cates, and we screened the remaining 1133 reports to identify
potentially relevant studies. We obtained three full-text copies of
reports of studies for further investigation (Ezra 2004; Freeman
1997, Kim 1996). These three studies met the inclusion criteria,
and we included them in the review.
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Figure 1. Results from searching for studies for inclusion in the review.
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Included studies
We included three studies in the review: Ezra 2004, Freeman 1997,
and Kim 1996. See the ’Characteristics of included studies’ table
for more information.
The studies provided data on the comparison between vitrectomy
and observation in eyes with macular hole and visual acuity less
than 20/50. Kim 1996 and Freeman 1997 were conducted in
the USA, used a similar protocol, and included people with stage
II macular hole (Kim 1996: 42 eyes randomised, 36 analysed,
number of participants not reported) or people with stage III/IV
hole (Freeman 1997: 129 eyes of 120 participants, 115 eyes in
analyses). Ezra 2004 was conducted in the UK and included 185
eyes of 174 participants with full-thickness macular hole (41 eyes
with stage II holes and 74 eyes with stage III/IV holes in analyses).
Types of participants
Ezra 2004 included 185 eyes of 174 participants with full-thick-
ness macular hole stage II-IV, with visual acuity less than 20/60,
duration less than 9months, and positive Watzke-Allen test result.
Freeman 1997 included 120 participants with stage III and IV
macular holes, visual acuity less than 20/50, decreasing subjective
vision, hole tissue loss at least 400 micron in diameter, and positive
Watzke-Allen test result.
Kim1996 included 42 eyes enrolled in theVitrectomy forMacular
Hole Study with stage II macular hole. Inclusion criteria were:
eccentric macular hole diameter between 100 and 650 micron,
centric diameter less than 300 micron and a dark yellow ring,
positive Watzke-Allen test result.
Types of interventions
Ezra 2004 randomised eyes to three arms: (a) observation, (b)
vitrectomy, and (c) vitrectomy plus autologous serum. We used
only the vitrectomy group as the intervention group and did not
consider data for the vitrectomy plus serum arm.
Freeman 1997 randomised eyes to vitrectomy or observation.
Kim 1996 randomised eyes to vitrectomy or observation.
Types of outcomes
Ezra 2004 did not define primary and secondary outcomes. Out-
comes reported in the study at 12 and 24 months were anatomic
closure of the hole and visual acuity.
Freeman 1997 did not define primary and secondary outcomes.
Outcomes reported in the study at six months were for measures of
best-corrected visual function, standardised photographic evalua-
tion of the extent of hole closure, evaluation of lens opacification,
and adverse events.
Kim 1996 did not define primary and secondary outcomes. Out-
comes reported in the study at 6 and 12 months were measures
of visual function, including our primary outcome visual acuity,
standardised photographic evaluation of the extent of hole closure,
evaluation of lens opacification, and adverse events.
Excluded studies
We did not exclude any studies after reviewing the full text. In
addition, we could not find any ongoing studies comparing vit-
rectomy with observation in people with macular hole, which was
as expected due to the established nature of this surgical interven-
tion.
Risk of bias in included studies
We have summarised the ’Risk of bias’ assessment in Figure 2.
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Figure 2. ’Risk of bias’ summary: review authors’ judgements about each risk of bias item for each included
study.
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Allocation
All studies were at low risk of bias regarding random sequence
generation and allocation concealment.
Blinding
The main issue in all studies concerned lack of masking of partici-
pants to treatment assignment, which is unavoidable for a surgical
intervention. Moreover, Ezra 2004 did not mask investigators as-
sessing the recurrence of the macular hole and Freeman 1997 and
Kim 1996 did not mask visual acuity examiners.
Incomplete outcome data
Missing data in the control and treatment arm were 3% and 5%
in Ezra 2004, 11% and 6% in Freeman 1997, and 13% and 19%
in Kim 1996, respectively. Although no study reported on causes
of loss to follow-up, Freeman 1997 presented baseline data for
participants lost versus not lost to follow-up, finding little differ-
ences. Taking all these features into account, we did not consider
missing data a significant source of bias.
Selective reporting
Only Freeman1997 andEzra 2004 reported a prespecifiedprimary
endpoint, and it coincided with our primary outcome measure
of mean visual acuity. Table 1 shows that mean visual acuity was
reported consistently only at six months. In fact, we had to use
6-month data for Freeman 1997 in the primary analysis at 12
months since the follow-up was shorter in this study, which was
consistent with our original protocol. Furthermore, visual acuity
in vitrectomised and control eyes was relatively stable after six
months in Kim 1996 and Ezra 2004.
Other potential sources of bias
Finally, Freeman 1997 andEzra 2004 reported that a small number
of participants (6.8%) had both eyes included in the study, and
Kim 1996 did not report whether eyes and participants differed.
We considered this to not be a problem since macular hole is
generally a unilateral disease.
Effects of interventions
See: Summary of findings for the main comparison Vitrectomy
compared to observation for idiopathic macular hole
All data were available in published reports. We have summarised
results for important outcomes in the Summary of findings for the
main comparison.
Primary outcome
At 6 months in Freeman 1997 or 12 months in Ezra 2004 and
Kim 1996, visual acuity was improved by about 1.5 Snellen lines
(pooled estimate -0.16 logMAR; 95% CI -0.23 to -0.09, 3 studies
with 270 eyes, Analysis 1.1; Figure 3). There was no statistical het-
erogeneity in this analysis (I2 equals 0%), and the point estimates
of effect were about the same.
Figure 3. Forest plot of comparison: 1 Vitrectomy versus observation, outcome: 1.1 Mean visual acuity
(logMAR) at 6 to 12 months.
Secondary outcomes
Ezra 2004 found a similar improvement of about 1.5 lines of
visual acuity at 3 months, and an improvement of 2.5 lines at 24
months (Analysis 1.2; Analysis 1.3), which they related to cataract
extraction, a procedure that is more common in the second year.
Vitrectomy greatly increased the chances of macular hole closure
at 6 to 12 months (OR 31.4; 95% CI 14.9 to 66.3, 265 eyes,
Analysis 1.4; Figure 4). The success rate in the vitrectomy arm
versus the observation arm was in fact 80% versus 29% in Kim
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1996 (stage II holes), 69% versus 4% in Freeman 1997 (stage
III/IV holes), and 82% versus 12% in Ezra 2004 (mixed stage),
respectively.
Figure 4. Forest plot of comparison: 1 Vitrectomy versus observation, outcome: 1.4 Hole closure at 6 to 12
months.
Kim 1996 and Freeman 1997 reported reading acuity at six
months, which was better in the vitrectomy arm than in the ob-
servation arm by -0.17 logMAR (95% CI -0.07 to -0.26, Analysis
1.5). Freeman 1997 also reported reading speed at six months,
which was better in the vitrectomy arm than in the observation
arm (Analysis 1.6), although the improvement was not statistically
significant.
Harms
The most commonly reported event was cataract, referred to as
nuclear sclerosis score with no reference to the measurement tool.
Freeman 1997 reported values of 2.4 (standard deviation (SD):
0.1) and 1.3 (SD: 0.1) respectively for the vitrectomy and control
groups at six months. Ezra 2004 reported a progression of nuclear
sclerosis from 0.9 (SD: 0.4) at baseline to 1.9 (SD: 0.7) at six
months and 2.3 (SD: 0.9) at 24 months, and cataract surgery rates
of 19% at one year and 53% at two years, but did not give the
control figures. Kim 1996 reported five (33%) events: one cataract
and four abnormalities of retinal pigment epithelium.
Freeman 1997 did not report retinal detachment, which is a severe,
expected adverse event of vitrectomy. Freeman 1997 recorded one
case of endophthalmitis.
Ezra 2004 described the retinal detachment rate for the vitrec-
tomy groups only (vitrectomy alone or with serum), with values
of 7 of 124 (5.6%), most detachments occurring in the first 6
weeks. Symptomatic visual field defects in the inferotemporal sec-
tor were found in 4 of 124 eyes (3.2%), with 15 eyes (12.1%)
having asymptomatic defects. A second operation was needed in
18 (14.5%) of the surgical eyes, with subsequent hole closure in
78% of cases.
Predictors of clinical outcome
Ezra 2004 reported within-study subgroup data, finding a treat-
ment benefit both for smaller and more recent holes (stage II) and
for larger holes (stage III and IV), although smaller holes in the
control group closed spontaneously in 5 out of 24 participants.
Kim1996was conducted on stage II holes, andFreeman 1997 used
a similar protocol including stage III/IV holes. We could therefore
conduct Analysis 1.7, confirming that a benefit was found both
for stage II and for stage III/IV holes and demonstrating no sig-
nificant subgroup difference.
Quality of the evidence
The quality of the evidence for the primary outcome was mod-
erate due to lack of masking of visual acuity in two studies (-1
for risk of bias). For secondary outcomes, hole closure assessment
was unmasked in one study, but there was no quality downgrade
because treatment effect was strong. Additionally, the quality of
the evidence for key secondary outcomes was low due to the un-
certainty of the estimates (-1 for imprecision). See Summary of
findings for the main comparison.
D I S C U S S I O N
Summary of main results
We found three RCTs, conducted almost 10 years apart, that
showed similar benefits with vitrectomy for macular hole com-
pared to observation. The studies included participants with vi-
sual acuity lower than 20/50 and at stages II to IV. At 6 or 12
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months, visual acuity was improved by about 1.5 Snellen lines in
the studies comparing vitrectomy and observation groups, and the
chances of macular hole closure were increased by more than four
times, with hole closure occurring on average in about 76% versus
11% in the vitrectomy and observation arms, respectively.
We found a benefit regardless of hole stage, although smaller holes
were reported to have more chance of improvement than larger
holes (about 90% versus 70% closed with vitrectomy). We must
also consider that smaller holes may have more chance of sponta-
neous closure than larger holes.
Overall completeness and applicability of
evidence
The included studies were conducted about 10 and 20 years ago,
and vitrectomy techniques have improved since, particularly with
the introduction of small-gauge vitrectomy and ILM peeling.
Other technical improvements include the use of a dye to stain
ILM, the type of tamponade used, and the position of the patient
after the surgery. Other Cochrane reviews have previously inves-
tigated these topics (Solebo 2011; Spiteri Cornish 2013).
The included studies used different methods to evaluate hole clo-
sure.While in Ezra 2004 the hole closure was evaluated by one ob-
server by means of fundoscopy, photography, and fluorescein an-
giography, in Kim 1996 and Freeman 1997 the closure was graded
by an independent photograph-reading centre. Modern research
uses optical coherence tomography to assess macular hole closure
more objectively and precisely. We also suggest that predictors of
hole closure and surgical complications can be studied in larger
non-comparative studies, since there is little spontaneous variation
of average visual acuity in untreated macular holes.
Other sources of heterogeneity were not a problem in this review,
particularly different follow-up length, since visual function was
found stable from 6 to 12 months in the largest study.
We did not find RCTs on surgical treatment of stage I holes. Phar-
macological alternatives, that is intravitreal ocriplasmin (Stalmans
2012), are available to treat specific types of vitreomacular traction
syndrome, whether associated with small macular holes or not.
The main severe complications of vitrectomy we recorded in our
review was iatrogenic retinal detachment, which occurred in about
5% of cases in the largest and most recent study, but this risk was
imprecisely estimated due to the small sample size. A more recent,
large series of small gauge vitrectomies for epiretinal membrane
and macular hole found a lower detachment rate of 2.4% in 656
holes and 1.2% in 1206 epiretinal membranes (1.7% overall) (
Rizzo 2010).
The studies included in this review used vitrectomy techniques
that did not permit the study of many of the predictors of visual re-
covery after macular hole surgery. In a recent analysis from a mul-
ticentre database study in the UK, a total of 1078 eyes from 1045
participants were followed for a median follow-up of 0.6 years.
The study found an improvement of 0.3 logMAR (3 Snellen lines)
in about half of participants at six months and almost 60% at one
year, while less than 10% deteriorated by 0.30 logMAR units, sug-
gesting improved visual outcomes with modern vitrectomy tech-
niques (Jackson 2013; Steel 2013). A review of non-comparative
studies reported that macular hole stage and size, symptom dura-
tion and preoperative visual acuity, and several morphological pa-
rameters with OCT could be predictors of better visual outcome
(Kusuhara 2014). Although based on earlier techniques, our re-
view did not find the OR of hole closure closure differed in stage
II compared to stage III/IV macular holes.
Quality of the evidence
The quality of the evidence was moderate for primary efficacy
outcome as we found that masking of outcome assessors was not
attempted or was unclear in all the studies. The quality of the
evidence was low for harms such as retinal detachment, which
cannot be estimated precisely in RCTs of this size.
Potential biases in the review process
Some secondary outcomes were not measured and reported simi-
larly or consistently between the studies.
Agreements and disagreements with other
studies or reviews
We found two Cochrane systematic reviews that did not compare
vitrectomy to observation as in the current review, but wanted
to explore the benefit of different surgical and postsurgical ap-
proaches, as described below.
Solebo 2011 aimed to evaluate the evidence of the impact of post-
operative face-down positioning on the outcome of surgery for
macular hole and included three RCTs (Guillaubey 2008; Lange
2012;Tadayoni 2011). Even if therewas insufficient evidence from
which to draw firm conclusions about the impact of postopera-
tive face-down positioning on the outcome of surgery for macular
hole, two of the RCTs suggested a benefit in larger holes, but none
demonstrated evidence of a benefit in smaller holes.
Spiteri Cornish 2013 aimed to determine whether ILM peeling
improves anatomical and functional outcomes of macular hole
surgery compared with the no-peeling technique and included
four RCTs (Christensen 2009; Kwok 2005; Lois 2011; Tadayoni
2009). Although the authors found no evidence of a benefit of
ILM peeling in terms of the primary outcome (visual acuity at
six months), ILM peeling appears to be superior as it offers more
favourable cost effectiveness by increasing the likelihood of pri-
mary anatomical closure, subsequently decreasing the likelihood
of further surgery, with no differences in unwanted side effects
compared with no peeling.
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A U T H O R S ’ C O N C L U S I O N S
Implications for practice
Vitrectomy is effective in improving visual acuity, resulting in a
moderate visual gain, and in achieving hole closure in people with
macular hole. However, these results may not apply to modern
surgery, since vitrectomy techniques have improved since the stud-
ies were conducted, particularly with the introduction of small-
gauge vitrectomy and ILMpeeling.Other technical improvements
include the use of a dye to stain ILM, the type of tamponade used,
and the position of the patient after the surgery (Solebo 2011;
Spiteri Cornish 2013).
Implications for research
A systematic review comparing small-gauge to conventional vit-
rectomy in people with macular hole is needed.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Ezra 2004
Methods Randomised clinical trial conducted in the UK
Participants 185 eyes of 174 participants with full-thickness macular hole
Inclusion criteria: symptom duration < 9 months, visual acuity 20/60, positive Watzke-
Allen test result, full-thickness macular hole stage II, III, or IV
Interventions 3 arms: (a) observation, (b) vitrectomy, (c) vitrectomy plus autologous serum
Outcomes Predefined: anatomic closure of the hole and visual acuity
Notes Authors declare no relevant conflict of interest. Funding sources reported: grant
GREZ0195 from the Guide Dogs for the Blind Association, London, England,
and grant EZRE0311 from the Stringer Bequest to the Special Trustees of Moorfields
Eye Hospital
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “The allocation schedule involved
computer generated randomizations cards
using the ’block’ method”
Allocation concealment (selection bias) Low risk Quote: “Serially numbered, sealed opaque
envelopes were used to conceal individ-
ual allocations. Assignment occurred at the
end of the entry visit, when the envelope
was opened. All envelopes were held and
opened by the study coordinator (M.D.),
who acted as executor and held the alloca-
tion sequence code. The executor, alloca-
tion schedule generators, assessors, and sur-
geon were separate individuals.”
Blinding of participants and personnel
(performance bias)
Hole closure
Low risk Unmasked, but hole closure is an anatomic
outcome and no such bias is expected
Blinding of participants and personnel
(performance bias)
Visual acuity
High risk Unmasked, and visual acuity is a subjective
outcome that can be influenced by partici-
pants’ knowledge of allocation status
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Ezra 2004 (Continued)
Blinding of outcome assessment (detection
bias)
Hole closure
High risk Quote: “One observer, using the fundus-
copic, photographic, and fluorescein an-
giography, assessed the hole status. As far
as funduscopic assessment was concerned,
it was not possible to postoperatively mask
between surgery and observation, as exami-
nation alone would reveal whether a vitrec-
tomy had been performed. However, the
assessorwasmasked as far as vitrectomy ver-
sus vitrectomyplus serum, as it was not pos-
sible to distinguish between them on clin-
ical grounds.”
Comment: judgement could be biased
Blinding of outcome assessment (detection
bias)
Visual acuity
Low risk Quote: “The assessor of visual acuity (A.M.
) was masked to the allocation status.”
Incomplete outcome data (attrition bias)
All outcomes
Low risk At 12 months: 2, 3, and 1 participants were
lost in observation, vitrectomy, and vitrec-
tomy plus serum groups respectively
At 24 months: 3, 3, and 3 participants were
lost in observation, vitrectomy, and vitrec-
tomy plus serum groups respectively
Selective reporting (reporting bias) Low risk Predefined primary outcomes
Other bias Low risk A small number of participants (11) had
both eyes included in the study. No other
source of bias
Freeman 1997
Methods A multicentre, randomised clinical trial in USA. Study began in June 1992 and was
published in 1997
Participants 129 eyes of 120 participants with stage III and IV macular holes; relevant inclusion
criteria were visual acuity less than 20/50, decreasing subjective vision, hole tissue loss
at least 400 micron in diameter, positive Watzke-Allen test result
Interventions Vitrectomy versus observation
Outcomes 4measures of best-corrected visual function, standardised photographic evaluation of the
extent of hole closure, evaluation of lens opacification, and adverse events at 6 months
Notes No conflict of interest declaration reported in themanuscript. Funding sources: potential
conflict of interest related to funding by Alcon Inc, Fort Worth, Texas, as surgical device
producer. Other sources: grant from Research to Prevent Blindness Inc, New York, NY;
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Freeman 1997 (Continued)
and EY-03040 Core Grant from National Eye Institute
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated random sequence
Allocation concealment (selection bias) Low risk Randomisation code delivered in an enve-
lope only after the participant had been
judged to be eligible and agreed to enter the
study
Blinding of participants and personnel
(performance bias)
Hole closure
Low risk Unmasked, but hole closure is an anatomic
outcome and no such bias is expected
Blinding of participants and personnel
(performance bias)
Visual acuity
High risk Unmasked, and visual acuity is a subjective
outcome that can be influenced by partici-
pants’ knowledge of allocation status
Blinding of outcome assessment (detection
bias)
Hole closure
Low risk Independent photograph-reading centre
Blinding of outcome assessment (detection
bias)
Visual acuity
High risk Unmasked visual acuity examiners
Incomplete outcome data (attrition bias)
All outcomes
Low risk At 6 months, 4/64 eyes versus 7/65 eyes
were lost in vitrectomy group and observa-
tion group, respectively
Selective reporting (reporting bias) Low risk A protocol was not available, nor were pre-
defined outcomes declared. However, hole
closure andmean logMAR visual acuity are
key expected outcomes in this research field
Other bias Low risk No other source of bias
Kim 1996
Methods A multicentre, randomised clinical trial in USA conducted between 1991 and 1994
Participants 42 of 213 eyes enrolled in the Vitrectomy for Macular Hole Study had stage II macular
hole. Inclusion criteria: Eccentric macular hole diameter between 100 and 650 micron,
centric macular hole diameter less than 300 micron and a dark yellow ring, positive
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Kim 1996 (Continued)
Watzke-Allen test result
Interventions Vitrectomy versus observation
Outcomes 4 measures of best-corrected visual function, standardised photographic evaluation of
the extent of hole closure, evaluation of lens opacification, and adverse events at 6 and
12 months
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated random sequence
Allocation concealment (selection bias) Low risk Quote: “Each center opened a sealed enve-
lope containing the randomization card for
a given patient after informed consent was
signed”
Blinding of participants and personnel
(performance bias)
Hole closure
Low risk Unmasked, but hole closure is an anatomic
outcome and no such bias is expected
Blinding of participants and personnel
(performance bias)
Visual acuity
High risk Unmasked, and visual acuity is a subjective
outcome that can be influenced by partici-
pants’ knowledge of allocation status
Blinding of outcome assessment (detection
bias)
Hole closure
Low risk Masked reading of the fundus pho-
tographs. Two photograph readers read
fundus photographs. Where the 2 princi-
pal photograph readers were not in com-
plete agreement, the images were reviewed
by the principal investigator and by a fun-
dus photographer reader from an outside
institution
Blinding of outcome assessment (detection
bias)
Visual acuity
High risk Unmasked visual acuity examiners
Incomplete outcome data (attrition bias)
All outcomes
Low risk At 12 months 2/15 and 4/21 were lost in
vitrectomy group and observation group,
respectively
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Kim 1996 (Continued)
Selective reporting (reporting bias) Low risk A protocol was not available, nor were pre-
defined outcomes. However, hole closure
and mean logMAR visual acuity are key ex-
pected outcomes in this research field
Other bias Low risk No other source of bias
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D A T A A N D A N A L Y S E S
Comparison 1. Vitrectomy versus observation
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Mean visual acuity (logMAR) at
6-12 months
3 273 Mean Difference (IV, Fixed, 95% CI) -0.16 [-0.23, -0.09]
2 Mean visual acuity (logMAR) at
3 months
1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
3 Mean visual acuity (logMAR) at
24 months
1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
4 Hole closure at 6-12 months 3 265 Odds Ratio (M-H, Fixed, 95% CI) 31.41 [14.90, 66.25]
5 Reading acuity at 6 months 2 154 Mean Difference (IV, Fixed, 95% CI) -0.17 [-0.26, -0.07]
6 Reading speed (word/minute) at
6 months
1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
7 Hole closure at 6-12 months 3 265 Odds Ratio (M-H, Fixed, 95% CI) 38.93 [16.88, 89.78]
7.1 Stage II hole 2 77 Odds Ratio (M-H, Fixed, 95% CI) 22.98 [6.33, 83.46]
7.2 Stage III/IV hole 2 188 Odds Ratio (M-H, Fixed, 95% CI) 54.28 [18.05, 163.
26]
Analysis 1.1. Comparison 1 Vitrectomy versus observation, Outcome 1 Mean visual acuity (logMAR) at 6-12
months.
Review: Vitrectomy for idiopathic macular hole
Comparison: 1 Vitrectomy versus observation
Outcome: 1 Mean visual acuity (logMAR) at 6-12 months
Study or subgroup Vitrectomy Observation
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Ezra 2004 59 0.53 (0.3) 60 0.69 (0.25) 51.2 % -0.16 [ -0.26, -0.06 ]
Freeman 1997 60 0.76 (0.31) 58 0.92 (0.305) 41.0 % -0.16 [ -0.27, -0.05 ]
Kim 1996 15 0.49 (0.41) 21 0.6 (0.34) 7.9 % -0.11 [ -0.36, 0.14 ]
Total (95% CI) 134 139 100.0 % -0.16 [ -0.23, -0.09 ]
Heterogeneity: Chi2 = 0.14, df = 2 (P = 0.93); I2 =0.0%
Test for overall effect: Z = 4.31 (P = 0.000017)
Test for subgroup differences: Not applicable
-0.2 -0.1 0 0.1 0.2
Favours vitrectomy Favours observation
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Analysis 1.2. Comparison 1 Vitrectomy versus observation, Outcome 2 Mean visual acuity (logMAR) at 3
months.
Review: Vitrectomy for idiopathic macular hole
Comparison: 1 Vitrectomy versus observation
Outcome: 2 Mean visual acuity (logMAR) at 3 months
Study or subgroup Vitrectomy Observation
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Ezra 2004 57 0.55 (0.25) 60 0.7 (0.25) -0.15 [ -0.24, -0.06 ]
-0.2 -0.1 0 0.1 0.2
Favours vitrectomy Favours observation
Analysis 1.3. Comparison 1 Vitrectomy versus observation, Outcome 3 Mean visual acuity (logMAR) at 24
months.
Review: Vitrectomy for idiopathic macular hole
Comparison: 1 Vitrectomy versus observation
Outcome: 3 Mean visual acuity (logMAR) at 24 months
Study or subgroup Vitrectomy Observation
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Ezra 2004 59 0.45 (0.34) 53 0.7 (0.27) -0.25 [ -0.36, -0.14 ]
-0.2 -0.1 0 0.1 0.2
Favours vitrectomy Favours observation
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Analysis 1.4. Comparison 1 Vitrectomy versus observation, Outcome 4 Hole closure at 6-12 months.
Review: Vitrectomy for idiopathic macular hole
Comparison: 1 Vitrectomy versus observation
Outcome: 4 Hole closure at 6-12 months
Study or subgroup Vitrectomy Observation Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Ezra 2004 46/56 7/59 42.7 % 34.17 [ 12.03, 97.08 ]
Freeman 1997 40/58 2/56 22.2 % 60.00 [ 13.16, 273.51 ]
Kim 1996 12/15 6/21 35.1 % 10.00 [ 2.06, 48.56 ]
Total (95% CI) 129 136 100.0 % 31.41 [ 14.90, 66.25 ]
Total events: 98 (Vitrectomy), 15 (Observation)
Heterogeneity: Chi2 = 2.74, df = 2 (P = 0.25); I2 =27%
Test for overall effect: Z = 9.05 (P < 0.00001)
Test for subgroup differences: Not applicable
0.005 0.1 1 10 200
Favours observation Favours vitrectomy
Analysis 1.5. Comparison 1 Vitrectomy versus observation, Outcome 5 Reading acuity at 6 months.
Review: Vitrectomy for idiopathic macular hole
Comparison: 1 Vitrectomy versus observation
Outcome: 5 Reading acuity at 6 months
Study or subgroup Vitrectomy Observation
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Freeman 1997 60 0.89 (0.3098) 58 1.03 (0.3046) 72.7 % -0.14 [ -0.25, -0.03 ]
Kim 1996 15 0.59 (0.31) 21 0.83 (0.21) 27.3 % -0.24 [ -0.42, -0.06 ]
Total (95% CI) 75 79 100.0 % -0.17 [ -0.26, -0.07 ]
Heterogeneity: Chi2 = 0.85, df = 1 (P = 0.36); I2 =0.0%
Test for overall effect: Z = 3.47 (P = 0.00052)
Test for subgroup differences: Not applicable
-0.5 -0.25 0 0.25 0.5
Favours vitrectomy Favours observation
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Analysis 1.6. Comparison 1 Vitrectomy versus observation, Outcome 6 Reading speed (word/minute) at 6
months.
Review: Vitrectomy for idiopathic macular hole
Comparison: 1 Vitrectomy versus observation
Outcome: 6 Reading speed (word/minute) at 6 months
Study or subgroup Vitrectomy Observation
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Freeman 1997 60 30 (20.9141) 58 35.6 (27.4168) -5.60 [ -14.42, 3.22 ]
-20 -10 0 10 20
Favours observation Favours vitrectomy
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Analysis 1.7. Comparison 1 Vitrectomy versus observation, Outcome 7 Hole closure at 6-12 months.
Review: Vitrectomy for idiopathic macular hole
Comparison: 1 Vitrectomy versus observation
Outcome: 7 Hole closure at 6-12 months
Study or subgroup Vitrectomy Observation Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Stage II hole
Ezra 2004 18/18 5/23 5.6 % 124.45 [ 6.41, 2415.97 ]
Kim 1996 12/15 6/21 43.5 % 10.00 [ 2.06, 48.56 ]
Subtotal (95% CI) 33 44 49.0 % 22.98 [ 6.33, 83.46 ]
Total events: 30 (Vitrectomy), 11 (Observation)
Heterogeneity: Chi2 = 2.31, df = 1 (P = 0.13); I2 =57%
Test for overall effect: Z = 4.76 (P < 0.00001)
2 Stage III/IV hole
Ezra 2004 28/38 2/36 23.5 % 47.60 [ 9.63, 235.40 ]
Freeman 1997 40/58 2/56 27.5 % 60.00 [ 13.16, 273.51 ]
Subtotal (95% CI) 96 92 51.0 % 54.28 [ 18.05, 163.26 ]
Total events: 68 (Vitrectomy), 4 (Observation)
Heterogeneity: Chi2 = 0.04, df = 1 (P = 0.84); I2 =0.0%
Test for overall effect: Z = 7.11 (P < 0.00001)
Total (95% CI) 129 136 100.0 % 38.93 [ 16.88, 89.78 ]
Total events: 98 (Vitrectomy), 15 (Observation)
Heterogeneity: Chi2 = 3.81, df = 3 (P = 0.28); I2 =21%
Test for overall effect: Z = 8.59 (P < 0.00001)
Test for subgroup differences: Chi2 = 0.99, df = 1 (P = 0.32), I2 =0.0%
0.002 0.1 1 10 500
Favours vitrectomy Favours observation
A D D I T I O N A L T A B L E S
Table 1. Selective outcome reporting matrix: primary outcome ’mean visual acuity’
Follow-up
Study 3 months 6 months 12 months 24 months
Kim 1996 G reported reported F
Freeman 1997 G reported F
(6 months used)
F
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Table 1. Selective outcome reporting matrix: primary outcome ’mean visual acuity’ (Continued)
Ezra 2004 reported reported reported reported
Missing outcomes classification adapted from a list provided by PaulaWilliamson at a Cochrane training workshop on selective outcome
reporting bias; Edinburgh, March 2009:
A: States outcome analysed but only reported that P value > 0.05, i.e. not significant.
B: States outcome analysed but only reported that P value < 0.05.
C: Clear that outcome was analysed but insufficient data presented to be included in meta-analysis or full tabulation.
D: Clear that outcome was analysed but no results reported.
E: Clear that outcome was measured (e.g. includes structurally related outcomes) but not necessarily analysed.
F: States that outcome was not measured.
G: Not mentioned, but clinical judgement says likely to have been measured.
H: Not mentioned, but clinical judgement says unlikely to have been measured.
I: Other (to be specified)
A P P E N D I C E S
Appendix 1. CENTRAL search strategy
#1 MeSH descriptor Retinal Perforations
#2 macula* near/3 hole*
#3 (#1 OR #2)
#4 MeSH descriptor Vitrectomy
#5 vitrectom*
#6 PPV
#7 (#4 OR #5 OR #6)
#8 (#3 AND #7)
Appendix 2. MEDLINE search strategy
1. randomized controlled trial.pt.
2. (randomized or randomised).ab,ti.
3. placebo.ab,ti.
4. dt.fs.
5. randomly.ab,ti.
6. trial.ab,ti.
7. groups.ab,ti.
8. or/1-7
9. exp animals/
10. exp humans/
11. 9 not (9 and 10)
12. 8 not 11
13. exp retinal perforations/
14. (macula$ adj3 hole$).tw.
15. or/13-14
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16. exp vitrectomy/
17. vitrectom$.tw.
18. PPV.tw.
19. or/16-18
20. 15 and 19
21. 12 and 20
The search filter for trials at the beginning of the MEDLINE strategy is from the published paper by Glanville et al (Glanville 2006).
Appendix 3. EMBASE search strategy
1. exp randomized controlled trial/
2. exp randomization/
3. exp double blind procedure/
4. exp single blind procedure/
5. random$.tw.
6. or/1-5
7. (animal or animal experiment).sh.
8. human.sh.
9. 7 and 8
10. 7 not 9
11. 6 not 10
12. exp clinical trial/
13. (clin$ adj3 trial$).tw.
14. ((singl$ or doubl$ or trebl$ or tripl$) adj3 (blind$ or mask$)).tw.
15. exp placebo/
16. placebo$.tw.
17. random$.tw.
18. exp experimental design/
19. exp crossover procedure/
20. exp control group/
21. exp latin square design/
22. or/12-21
23. 22 not 10
24. 23 not 11
25. exp comparative study/
26. exp evaluation/
27. exp prospective study/
28. (control$ or prospectiv$ or volunteer$).tw.
29. or/25-28
30. 29 not 10
31. 30 not (11 or 23)
32. 11 or 24 or 31
33. retina tear/
34. (macula$ adj3 hole$).tw.
35. or/33-34
36. exp vitrectomy/
37. vitrectom$.tw.
38. PPV.tw.
39. or/36-38
40. 35 and 39
41. 32 and 40
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Appendix 4. LILACS search strategy
macula$ and hole$ and vitrectom$ or PPV
Appendix 5. Web of Science CPCI-S search strategy
#5 #1 AND #4
#4 #2 OR #3
#3 TS=PPV
#2 TS=vitrectom*
#1 TS=macula* hole
Appendix 6. metaRegister of Controlled Trials search strategy
macula hole AND vitrectomy
Appendix 7. ClinicalTrials.gov search strategy
macula hole AND vitrectomy
Appendix 8. ICTRP search strategy
macula hole AND vitrectomy
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